Olema Pharmaceuticals, Inc. (OLMA) Stock Price & Analysis
Olema Pharmaceuticals, Inc. (OLMA) rose 4.92% to USD 10.45 as of June 10, 2026 at 00:25 UTC, according to Nexqual real-time market data.
OLMA last closed at USD 9.96; the session ranged USD 10.1–10.74 on volume of 1,008,867 shares. Market capitalization is $912.78M, with a 52-week range of USD 3.89–36.26 (NMS). Source: Nexqual, June 10, 2026 at 00:25 UTC.
Key Statistics (as of June 10, 2026 at 00:25 UTC)
| Price | USD 10.45 |
|---|---|
| Change | ▲ 4.92% (up) |
| Previous Close | USD 9.96 |
| Open | USD 10.2 |
| Day Range | USD 10.1 – 10.74 |
| 52-Week Range | USD 3.89 – 36.26 |
| Volume | 1,008,867 shares |
| Market Cap | $912.78M |
| Exchange | NMS |
Technical Analysis (OLMA)
Nexqual's technical model rates OLMA "SELL" based on 2 bullish and 5 bearish signals across 124 daily candles, as of June 10, 2026 at 00:25 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 28.03 (oversold) |
| vs SMA50 | Below (USD 14.24) |
| MACD | -1.21 (negative) |
Analyst Ratings (OLMA)
Wall Street analysts rate OLMA "Strong Buy" based on 11 analysts, with a mean price target of USD 41.36 (range USD 23–62), per Nexqual as of June 10, 2026 at 00:25 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 11 |
| Mean Target | USD 41.36 |
| High Target | USD 62 |
| Low Target | USD 23 |
| Buy / Hold / Sell | 12 / 1 / 0 |
Earnings (OLMA)
| Next Earnings Date | 2026-08-10 |
|---|---|
| EPS Estimate | USD -0.56 |
| Revenue Estimate | $0 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.52 vs est -0.54 ▲ beat |
| 2025-12-31 | USD -0.5 vs est -0.53 ▲ beat |
| 2025-09-30 | USD -0.49 vs est -0.45 ▼ miss |
| 2025-06-30 | USD -0.51 vs est -0.44 ▼ miss |
Source: Nexqual, June 10, 2026 at 00:25 UTC.
Financials & Fundamentals (OLMA)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -42.86% |
| Debt / Equity | 0.82 |
| Current Ratio | 10.88 |
| Total Cash | $505.35M |
| Total Debt | $3.96M |
| Free Cash Flow | $-78.80M |
Source: Nexqual, June 10, 2026 at 00:25 UTC.
Financial Health Score (OLMA)
Nexqual rates Olema Pharmaceuticals, Inc.'s overall financial health "Mixed" across five dimensions, as of June 10, 2026 at 00:25 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Strong — $505M cash vs $4M debt, net cash position |
| Cash Flow | Weak — Operating cash flow -$149M |
| Efficiency | Critical — ROE -43%, ROA -25.5% |
Ownership (OLMA)
| Insider Ownership | +1.80% |
|---|---|
| Institutional Ownership | +119.43% |
| Shares Outstanding | 87.35M |
| Float | 59.72M |
| Short % of Float | +16.12% |
Source: Nexqual, June 10, 2026 at 00:25 UTC.
Leadership (OLMA)
Olema Pharmaceuticals, Inc. is led by Sean P. Bohen (age 58), President, CEO, Interim Principal Financial Officer & Director, per Nexqual as of June 10, 2026 at 00:25 UTC.
| President, CEO, Interim Principal Financial Officer & Director | Sean P. Bohen (age 58) |
|---|---|
| Chief Scientific Officer | David C. Myles (age 62) |
| Vice President of Corporate Communications | Courtney O'Konek |
| Senior Vice President of Clinical Development Operations | Richard Hernandez |
| Senior Vice President of Clinical Development | Mark Shilkrut |
Major Backers & Investors (OLMA)
Notable institutional backers of Olema Pharmaceuticals, Inc. include FMR, LLC, Paradigm Biocapital Advisors LP, Bain Capital Life Sciences Investors, LLC, according to Nexqual as of June 10, 2026 at 00:25 UTC.
Active Investors
| Investor | Stake |
|---|---|
| FMR, LLC | 11.89% |
| Paradigm Biocapital Advisors LP | 9.18% |
| Bain Capital Life Sciences Investors, LLC | 8.56% |
| Janus Henderson Group PLC | 8.14% |
| BVF Inc. | 6.06% |
| Fidelity | 5.46% |
| Siren, L.L.C. | 5.45% |
| Cormorant Asset Management, LP | 4.46% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 8.36% |
| State Street | 7.64% |
Source: Nexqual, June 10, 2026 at 00:25 UTC.
From Olema Pharmaceuticals, Inc.'s Latest SEC 10-K Filing (filed 2026-03-16)
Key Strengths & Strategy (as disclosed to the SEC)
- Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers.
- It also develops OP-3136, an orally-available small molecule that potently and selectively inhibits KAT6 which is in Phase 1 clinical trials for patients with breast and other solid tumor cancers.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| ORIC | Oric Pharmaceuticals, Inc. | USD 8 | ▲ 6.67% |
| CGEM | Cullinan Therapeutics, Inc. | USD 13.18 | ▼ 2.44% |
| PRAX | Praxis Precision Medicines, Inc | USD 250.33 | ▼ 1.44% |
| FDMT | 4D Molecular Therapeutics, Inc. | USD 9.23 | ▲ 6.83% |
| ALXO | ALX Oncology Holdings Inc. | USD 1.55 | ▲ 0.65% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 00:25 UTC. This page is informational and not investment advice.